Cystic fibrosis and the cardiovascular system: the unexpected heartache

Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis

(2023) Carolin Steinack et al.   Journal of Cystic Fibrosis

Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor

(2023) Lisa J. Meltzer et al.   Journal of Cystic Fibrosis

Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del

(2023) Andrea Lopez et al.   Journal of Cystic Fibrosis

Elexacaftor – Tezacaftor – Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study

(2023) Alexander Schnell et al.   Heliyon

Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study

(2023) Freddy Frost et al.   EUROPEAN RESPIRATORY JOURNAL

Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association

(2022) Donald M. Lloyd-Jones et al.   CIRCULATION

Elexacaftor–Tezacaftor–Ivacaftor improves exercise capacity in adolescents with cystic fibrosis

(2022) Adam J. Causer et al.   PEDIATRIC PULMONOLOGY

Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association

(2022) Xingxing S. Cheng et al.   CIRCULATION

Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study

(2022) Michal Gur et al.   PEDIATRIC PULMONOLOGY

Restoring myocardial infarction-induced long-term memory impairment by targeting the cystic fibrosis transmembrane regulator

(2022) Lotte Vanherle et al.   EBioMedicine

Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment

(2022) Vincenzo Carnovale et al.   Journal of Clinical Medicine

High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing

(2022) Sacha Spelier et al.   ERJ Open Research

Cardiovascular complications in cystic fibrosis: A review of the literature

(2021) T. Spencer Poore et al.   Journal of Cystic Fibrosis

Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis

(2021) Max C. Petersen et al.   Journal of Cystic Fibrosis

Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: A multicenter retrospective research network study

(2021) Yousaf B. Hadi et al.   RESPIRATORY MEDICINE

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥24 Weeks in People With CF and ≥1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial

(2020) Matthias Griese et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review

(2020) Renée V. E. Dagenais et al.   Journal of Clinical Medicine

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary

(2019) Donna K. Arnett et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults

(2016) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Protective Role of Cardiac CFTR Activation Upon Early Reperfusion Against Myocardial Infarction

(2012) Hiromi Uramoto et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY